INTRODUCTION
Peripheral T-cell lymphoma (PTCL) is a small subset of aggressive non-Hodgkin lymphomas (NHL) [1] . One of the rarer entities of PTCL is enteropathy associated T-cell lymphoma (EATL). In general, EATL is diagnosed upon immunophenotype of small intestine biopsy and is only associated with approximately 5% of gastrointestinal (GI) lymphomas and less than 1% of NHL [2] . EATL is most commonly found in adult populations with a high incidence of celiac disease [3] . However, EATL can be divided into type 1 disease, which is associated with celiac disease, and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), formally type 2, which is not associated with celiac disease [1] . MEITL is unique upon its immunophenotypic features compared to type 1 EATL [4] and has a higher incidence in Asian and Hispanic populations [5] . Ideal treatment of EATL consist of combination chemotherapy and hematopoietic cell transplantation (HCT) [6] . Here we present a unique case of EATL, in an African American patient without celiac disease.
CASE PRESENTATION

Chief complaints
A 60-yr-old African American female with a remote medical history of breast cancer, status post double mastectomy, presented with 1 wk of bilateral lower abdominal pain that was associated with diarrhea, early satiety, and a 30 lb. weight loss (over 3 mo).
Diagnostic evaluation
A computed tomography (CT) scan revealed a large circumferential mass involving the transverse colon which extended approximately 14 cm in length (Figure 1 A, B , and C). On physical exam, her vitals were stable. Her abdominal exam was soft and non-distended, with mild pain to palpation to her lower abdomen. Her laboratory work-up was notable for a mild leukocytosis (white blood count 13.4 bil/L, hemoglobin 15.7 g/dL, platelets 404 bil/L), hyponatremia and acute kidney injury ( sodium 123 mmol/L and creatinine 2.52 mg/dL (baseline creatinine was normal)). Her liver function tests (including albumin and protein level), lactic acid, lipase, infectious stool studies (i.e., Clostridium difficile infection, ova and parasites, Shiga toxin producing Escherichia coli, Salmonella, Shigella, Campylobacter, or Escherichia coli O157) were all normal.
She underwent an esophagogastroduodenoscopy (EGD) and colonoscopy. EGD was notable for non-erosive gastropathy and normal appearing duodenum for which biopsies were obtained. Colonoscopy was notable for nodular ileal and colonic mucosa with multiple colonic polyps ( Figure 2 ). In addition, she had a 15 cm malignant appearing stricture in the transverse colon ( Figure 3 ). The largest colonic polyp was approximately 2.5 cm in her rectum ( Figure 4 ). Pathology results of her stomach, duodenum, terminal ileum, colon, transverse stricture and all of her colonic polyps were notable for MEITL ( Figure 5 ). There was no evidence of celiac disease on duodenal biopsy. There was no evidence of adenocarcinoma throughout her colon.
For the patient's newly diagnosed high grade EATL, she underwent staging bone marrow biopsy and positron emission tomography (PET)/CT scan. Bone marrow biopsy was without overt morphologic or flow cytometry evidence of T-cell lymphoma or metastatic malignancy. PET/CT scan with abnormal F-18 fluorodeoxyglucose (FDG) activity associated with the transverse colonic mass, mesenteric lymphadenopathy, focal uptake within the rectum, intense uptake throughout the bone marrow, and portions of the spleen.
The patient was started on chemotherapy with EOCH (Etoposide, Oncovin, Cyclophosphamide, and Hydroxydaunorubicin). She was not a candidate for HCT given her functional status. Unfortunately, despite her aggressive chemotherapy regimen, her disease persisted. At her 6-month follow-up, her repeat PET/CT scan with abnormal FDG activity associated with the transverse colon and rectum. Repeat colonoscopy noted a large lymphoma polyploidy lesion.
FINAL DIAGNOSIS
The patient was diagnosed with EATL, immunochemical testing was not conclusive for MEITL however was suggestive of the disease.
TREATMENT
The patient underwent chemotherapy with EOCH (Etoposide, Oncovin, Cyclophosphamide, and Hydroxydaunorubicin).
OUTCOME AND FOLLOW-UP
At her 6-mo follow-up, her repeat PET/CT scan with abnormal FDG activity associated with the transverse colon and rectum. Repeat colonoscopy noted a large lymphoma polyploidy lesion.
DISCUSSION
EATL is a rare form of PTCL that generally effects middle aged Caucasians. The majority of cases involve the small intestine (up to 90%), while the stomach and colon are less commonly involved (35% and 8% respectively) [3, 4] . Additionally, many patients with EATL have celiac disease on histology [7] . Our patient is unique as she is an African American with involvement of entire GI tract, and no histological evidence of celiac disease.
Endoscopically, EATL often presents with nodularity, circumferential ulcers, and at times perforation. Identifiable masses or polyps are not generally appreciated [8] . In this case, the colonoscopy was notable for multiple large polyps (largest being 2.5 cm in the rectum) and a malignant appearing stricture.
Ideal treatment of EATL is consisted of combination chemotherapy and HCT. However, if patients are with poor functional status, HCT may not be an option. Sieniawski et al [6] demonstrated in a retrospective study that patients with EATL undergoing chemotherapy (ifosfamide, etoposide, epirubicin, and methotrexate) followed by HCT had progression free survival and overall survival (OS) at 5 yr of 52% and 60%, respectively. Chemotherapy alone has a much poorer prognosis with 5 yr OS of 10%-20% [8] . To review previous cases, we also performed a PubMed literature search. The search was conducted using the phrase "case report" and "monomorphic epitheliotropic intestinal T-cell lymphoma". Six articles were identified between 2016 and 2018, involving nine patients. The majority of cases reported were in Southeast Asia. The patient's ages ranged from 40 to 83 yr old and the majority of cases were male (66%). The most common presenting symptoms were diarrhea (44%) and weight loss (33%). Interestingly, one patient presented with severe dyspnea. The patient was noted to have a pleural effusion secondary to MEITL. Treatment regimens mainly consisted of various chemotherapy regimens with 33% of patients receiving stem cell transplants. Unfortunately, survival after diagnosis was poor and ranged from 5 d to 3 yr despite therapy (Table 1 ) [9] [10] [11] [12] [13] [14] .
CONCLUSION
In conclusion, our patient continues to undergo therapy. Her subsequent PET scan and endoscopy have identified persistent disease. Our case is limited in that the patient has yet to complete chemotherapy. At her 6-mo follow-up, her repeat PET/CT scan with abnormal FDG activity associated with the transverse colon and rectum. Repeat colonoscopy noted a large lymphoma polyploidy lesion. There is no gold standard for monitoring EATL and repeat endoscopies can be decided on a case-bycase basis with guidance from oncology and further repeat imaging. Ishibashi et al [10] 2016, Japan 70 y/o, Male Nausea Not stated SMILE Deceased at 9 mo Aiempanakit et al [11] 2017, Thialand 67 y/o, Male Chronic diarrhea and weight loss Not stated Anthracycline based chemotherapy Deceased at 2 mo Antoniadou et al [12] 2016 
